{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:03Z","timestamp":1786119243601,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,26]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Anaplastic lymphoma kinase (ALK) gene fusion, an important driver gene alteration leading to the development of lung cancer, occurs in 5% of nonsmall cell lung cancer (NSCLC) cases in China. In addition to echinoderm microtubule-associated protein-like 4 (EML4)-ALK, which is the most common type of ALK fusion, various fusion partner genes have been identified in recent years. However, ALK intergenic breakpoint fusions confound fusion detection and targeted treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 40-year-old woman presented to our hospital with a 2-month history of a cough.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis:<\/jats:title>\n                    <jats:p>Based on the right hilar lymph node biopsy and positron emission tomography computed tomography (PET-CT) examination, the patient was diagnosed with \u201cstage IV lung adenocarcinoma\u201d showing metastases in the mediastina, right hilar lymph nodes, and C7 vertebral body. A rare solute carrier family 8 member A1 (SLC8A1) downstream intergenic region ALK fusion was identified in biopsy specimens using next-generation sequencing (NGS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient received first-line molecular-targeted therapy (ceritinib).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>After nearly 9 months, the best evaluation of partial remission (PR) was obtained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This is the first clinical evidence of advanced NSCLC due to a rare SLC8A1 downstream intergenic region ALK fusion that has been effectively treated with ceritinib. Whether this finding represents an inherent property of this fusion protein or its unique clinicopathological characteristics in patients carrying this fusion protein remains to be investigated. Moreover, the patient\u2019s durable response to ceritinib and future resistance mechanisms require further follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000030255","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T10:09:31Z","timestamp":1661854171000},"page":"e30255","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Excellent response of lung adenocarcinoma harboring a rare SLC8A1 downstream intergenic region ALK fusion to ceritinib treatment: A case report"],"prefix":"10.1097","volume":"101","author":[{"given":"Lei","family":"Fang","sequence":"first","affiliation":[{"name":"Department of Geriatric Respiratory and Critical Care, Provincial Key Laboratory of Molecular Medicine for Geriatric Disease, Anhui Geriatric Institute, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozheng","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Pulmonary, Anqing Municipal Hospital, Anqing, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzi","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Pathology, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebo","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Geriatric Respiratory and Critical Care, Provincial Key Laboratory of Molecular Medicine for Geriatric Disease, Anhui Geriatric Institute, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peishan","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Geriatric Respiratory and Critical Care, Provincial Key Laboratory of Molecular Medicine for Geriatric Disease, Anhui Geriatric Institute, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Geriatric Respiratory and Critical Care, Provincial Key Laboratory of Molecular Medicine for Geriatric Disease, Anhui Geriatric Institute, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1035-3681","authenticated-orcid":false,"given":"Yanbei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Geriatric Respiratory and Critical Care, Provincial Key Laboratory of Molecular Medicine for Geriatric Disease, Anhui Geriatric Institute, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250707","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ctrv.2013.07.002","article-title":"ALK inhibitors in the treatment of advanced NSCLC.","volume":"40","author":"Gridelli","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"R2-20250707","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(16)31473-8","article-title":"New and emerging targeted treatments in advanced non-small-cell lung cancer.","volume":"388","author":"Hirsch","year":"2016","journal-title":"Lancet"},{"key":"R3-20250707","first-page":"100015","article-title":"Catalog of 5\u2019 fusion partners in ALK+ NSCLC circa 2020.","volume":"1","author":"Ou","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"R4-20250707","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jtho.2020.02.023","article-title":"Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in NSCLC.","volume":"15","author":"Li","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R5-20250707","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"R6-20250707","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"R7-20250707","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.","volume":"27","author":"Shaw","year":"2009","journal-title":"J Clin Oncol"},{"key":"R8-20250707","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"R9-20250707","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer.","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"R10-20250707","doi-asserted-by":"crossref","first-page":"120ra","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers.","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci Transl Med"},{"key":"R11-20250707","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov"},{"key":"R12-20250707","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jtho.2017.07.005","article-title":"ASCEND-8: a randomized phase 1 study of ceritinib, 450\u2009mg or 600\u2009mg, taken with a low-fat meal versus 750\u2009mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).","volume":"12","author":"Byoung","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R13-20250707","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1200\/JCO.2016.68.5891","article-title":"Differential sensitivity to crizotinib: does eml4-alk fusion variant matter?","volume":"34","author":"Lin","year":"2016","journal-title":"J Clin Oncol"},{"key":"R14-20250707","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2015.65.8732","article-title":"Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer.","volume":"34","author":"Yoshida","year":"2016","journal-title":"J Clin Oncol"},{"key":"R15-20250707","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18632\/genesandcancer.3","article-title":"ALK-rearrangements and testing methods in non-small cell lung cancer: a review.","volume":"5","author":"Shackelford","year":"2014","journal-title":"Genes Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000030255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:48:59Z","timestamp":1786038539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000030255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":15,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030255","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]}}}